Amanda Caputo
Nurse Practitioner · Lewes, DENPI 1851955678
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 151 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,133 and has fallen 61.4% since, to $437 in 2025. Among nurse practitioner clinicians in DE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 151 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$379
- Amgen$349
- Johnson & Johnson$285
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$251
- Boehringer Ingelheim$236
- Merck$215
- plus $1K from 14 others
What the payments were for
- Food & beverage$2,889100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 17 | $379 |
| Amgen | 15 | $349 |
| Johnson & Johnson | 15 | $285 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $251 |
| Boehringer Ingelheim | 13 | $236 |
| Merck | 12 | $215 |
| Novo Nordisk | 10 | $199 |
| Lexicon Pharmaceuticals, Inc. | 7 | $148 |
| Bayer | 6 | $132 |
| AstraZeneca | 8 | $126 |
| Kestra Medical Technology Services, Inc. | 8 | $118 |
| E.r. Squibb & Sons, L.L.C. | 7 | $116 |
| Pfizer | 6 | $102 |
| Esperion Therapeutics, Inc. | 4 | $78 |
| Scpharmaceuticals Inc. | 2 | $37 |
| Tactile Systems Technology Inc | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 2 | $33 |
| Actelion Pharmaceuticals US, Inc. | 1 | $27 |
| Medtronic | 1 | $21 |
| GSK | 1 | $16 |
How this compares
$2,903 in reported general payments places this provider in the 90th percentile of 487 nurse practitioner providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 113 | $149,827 |
| XareltoRivaroxaban | 47 | $58,566 |
| JardianceEmpagliflozin | 38 | $55,951 |
| EntrestoSacubitril/Valsartan | 37 | $47,353 |
| Repatha SureclickEvolocumab | 21 | $21,561 |
| Ranolazine ErRanolazine | 140 | $19,787 |
| Ezetimibe | 198 | $8,447 |
| Atorvastatin Calcium | 175 | $2,148 |
| Bisoprolol Fumarate | 65 | $1,620 |
| Metoprolol Succinate | 99 | $1,345 |
| Nitroglycerin | 120 | $1,130 |
| Rosuvastatin Calcium | 63 | $1,071 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 37 | $1,023 |
| ClopidogrelClopidogrel Bisulfate | 72 | $941 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 64 | $715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $102 | $149,827113 claims |
| Johnson & JohnsonXarelto | $285 | $58,56647 claims |
| Boehringer IngelheimJardiance | $236 | $55,95138 claims |
| NovartisEntresto | $379 | $47,35337 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 487 nurse practitioner providers in Delaware.
Other nurse practitioner in Lewes
- Shelby HoganLewes$5K
- Jennifer ShadeLewes$4K
- Susan ParksLewes$3K
- Jennifer WilleyLewes$3K
- Deborah TabulovLewes$2K
- Meghan McCarterSeaford$170K
- Chandni PatelMiddletown$113K
- Craig LaingMilford$51K
- Colleen DitroWilmington$16K
- Sedelle Henderson-BamideleNewark$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.